CA2146973C - Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques - Google Patents

Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques Download PDF

Info

Publication number
CA2146973C
CA2146973C CA002146973A CA2146973A CA2146973C CA 2146973 C CA2146973 C CA 2146973C CA 002146973 A CA002146973 A CA 002146973A CA 2146973 A CA2146973 A CA 2146973A CA 2146973 C CA2146973 C CA 2146973C
Authority
CA
Canada
Prior art keywords
tgf
beta
fragment
rii
excess
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002146973A
Other languages
English (en)
Other versions
CA2146973A1 (fr
Inventor
Patricia R. Segarini
James R. Dasch
David R. Olsen
Pedro A. Carrillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Publication of CA2146973A1 publication Critical patent/CA2146973A1/fr
Application granted granted Critical
Publication of CA2146973C publication Critical patent/CA2146973C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
CA002146973A 1992-10-29 1993-10-29 Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques Expired - Fee Related CA2146973C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96837592A 1992-10-29 1992-10-29
US3759793A 1993-03-26 1993-03-26
US07/968,375 1993-03-26
US08/037,597 1993-03-26
PCT/US1993/010455 WO1994009815A1 (fr) 1992-10-29 1993-10-29 UTILISATIONS D'UN FRAGMENT DE RECEPTEUR DU TGF-β COMME AGENT THERAPEUTIQUE

Publications (2)

Publication Number Publication Date
CA2146973A1 CA2146973A1 (fr) 1994-05-11
CA2146973C true CA2146973C (fr) 2008-09-02

Family

ID=26714287

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002146973A Expired - Fee Related CA2146973C (fr) 1992-10-29 1993-10-29 Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques

Country Status (8)

Country Link
US (1) US5693607A (fr)
EP (1) EP0669833B1 (fr)
JP (1) JPH08504763A (fr)
AU (1) AU669256B2 (fr)
CA (1) CA2146973C (fr)
DE (1) DE69332026T2 (fr)
ES (1) ES2174868T3 (fr)
WO (1) WO1994009815A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US7384634B2 (en) 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2122491A1 (fr) * 1991-10-31 1993-05-13 Herbert Y. Lin Sequences d'adnc du recepteur de type tgf-.beta. et leur utilisation
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69434617D1 (de) * 1993-11-19 2006-04-06 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
AU688409B2 (en) * 1993-11-19 1998-03-12 University Of Sydney, The A method for preventing or controlling cataract
US5866323A (en) 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
GB2304045A (en) * 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
WO1998046588A2 (fr) 1997-04-11 1998-10-22 Neorx Corporation Composes et therapies destines a la prevention d'affections vasculaires ou non vasculaires
WO1998048024A1 (fr) * 1997-04-18 1998-10-29 Biogen, Inc. Proteines de fusion contenant le recepteur type ii du tgf-beta et proteines de fusion en tant que region constante d'une immunoglobuline
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US20030180301A1 (en) * 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
US20090004182A1 (en) * 2004-10-13 2009-01-01 The Ohio State University Research Foundation Methods to Treat or Prevent Viral-Associated Lymphoproliferative Disorders
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
EP1998810A4 (fr) 2006-03-13 2009-09-02 Univ Johns Hopkins Augmentation de la thromborésistance endothéliale
DK2083863T3 (da) 2006-10-03 2015-06-22 Genzyme Corp Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
WO2008157367A1 (fr) * 2007-06-15 2008-12-24 Genzyme Corporation Protéines de fusion contenant deux domaines de liaison tgf-bêta du récepteur tgf-bêta de type ii
US8946201B2 (en) * 2007-08-27 2015-02-03 Saint Louis University Methods for inhibiting TGF-β
WO2010033507A1 (fr) * 2008-09-16 2010-03-25 St. Louis University Procédé d'amélioration de signalisation tgf-bêta
SI2835053T1 (sl) * 2010-03-12 2016-09-30 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
EP2660314A4 (fr) 2010-12-27 2014-09-03 Lsip Llc CELLULES SPi ET LEUR PROCÉDÉ DE PRODUCTION
EP2737083A1 (fr) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Méthodes de diagnostic et de traitement du syndrome de myhre
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
EP2799537B1 (fr) 2011-12-28 2021-09-22 Kyoto Prefectural Public University Corporation Normalisation d'une culture de cellules endothéliales de la cornée
WO2015027082A1 (fr) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Variants de type ii du récepteur de tgf-bêta et utilisations associées
RU2712967C2 (ru) 2013-10-31 2020-02-03 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтическое средство против заболеваний, связанных с гибелью клеток эндотелия роговицы, обусловленной состоянием эндоплазматического ретикулума
AR098827A1 (es) 2013-12-19 2016-06-15 Consejo Nac De Investig Científicas Y Técnicas (Conicet) ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
WO2016187312A1 (fr) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Procédés et compositions pour traiter une infection par alphavirus
AU2016301380B2 (en) 2015-08-04 2021-07-01 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
AU2018228435A1 (en) 2017-03-02 2019-10-03 National Research Council Of Canada TGF-beta-receptor ectodomain fusion molecules and uses thereof
US11021527B2 (en) 2017-05-04 2021-06-01 Acceleron Pharma Inc. Transforming growth factor beta receptor type II fusion polypeptides
JP7264827B2 (ja) 2017-05-12 2023-04-25 江蘇恒瑞医薬股▲ふん▼有限公司 ＴＧＦ－β受容体含有融合タンパク質およびそれらの医薬的用途
CA3093078A1 (fr) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Recepteurs d'antigene chimerique specifique a l'antigene prostatique specifique membranaire et leurs procedes d'utilisation
CA3093468A1 (fr) 2018-03-09 2019-09-12 Agenus Inc. Anticorps anti-cd73 et leurs procedes d'utilisation
WO2019246563A1 (fr) 2018-06-22 2019-12-26 Kite Pharma, Inc. Protéines transmembranaires chimériques et leurs utilisations
BR112021008288A2 (pt) 2018-11-09 2021-08-10 Jiangsu Hengrui Medicine Co., Ltd. composição farmacêutica de proteína de fusão do receptor tgf-ss e uso da mesma
WO2020201362A2 (fr) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes
US20230365653A1 (en) 2020-07-24 2023-11-16 Mabwell (shanghai) Bioscience Co., Ltd. Tgf-beta rii mutant and fusion protein thereof
US11945856B2 (en) 2022-01-28 2024-04-02 35Pharma Inc. Activin receptor type IIB variants and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
JP2612874B2 (ja) * 1986-10-02 1997-05-21 マサチユセツツ・インスチチユート・オブ・テクノロジー タンパク質の代謝的安定性を調節する方法
US5084384A (en) * 1987-04-23 1992-01-28 Monsanto Company Secretion of insulin-like growth factor-I
US5108919A (en) * 1988-06-24 1992-04-28 Genentech, Inc. Dna sequences encoding yeast ubiquitin hydrolase
CA2002011A1 (fr) * 1988-11-14 1990-05-14 Anthony F. Purchio Recepteur de tgf-beta regulateur de la croissance humaine normale
DE69032315T2 (de) * 1989-07-19 1998-10-01 Tonen Corp Peptidyl prolyl-cis.trans-isomersae
WO1991019513A1 (fr) * 1990-06-20 1991-12-26 Bristol-Myers Squibb Company PROCEDES DE MODULATION DE LA PRESSION SANGUINE A L'AIDE DU FACTEUR TRANSFORMANT DE CROISSANCE-β ET DE SES ANTAGONISTES
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
CA2122491A1 (fr) * 1991-10-31 1993-05-13 Herbert Y. Lin Sequences d'adnc du recepteur de type tgf-.beta. et leur utilisation
WO1993010215A1 (fr) * 1991-11-15 1993-05-27 Memorial Sloan-Kettering Cancer Center Proteaglicane betaglycane purifiee, compositions et procedes
MX9301135A (es) * 1992-03-06 1993-09-01 Steven G Reed Metodo para tratar infecciones por patogeno de macrofago.
EP0684828A4 (fr) * 1993-02-19 1996-08-07 Celtrix Pharma Expansion de cellules souches dans les cultures sur une longue duree de m lle osseuse par neutralisation du facteur de croissance transformant beta.
EP0637450A3 (fr) * 1993-08-04 1995-04-05 Collagen Corp Méthode et composition pour revigorer le tissu cicatriciel.
AU8016894A (en) * 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity

Also Published As

Publication number Publication date
WO1994009815A1 (fr) 1994-05-11
DE69332026T2 (de) 2002-10-31
CA2146973A1 (fr) 1994-05-11
EP0669833B1 (fr) 2002-06-12
DE69332026D1 (de) 2002-07-18
AU5665094A (en) 1994-05-24
EP0669833A1 (fr) 1995-09-06
ES2174868T3 (es) 2002-11-16
EP0669833A4 (fr) 1996-07-31
US5693607A (en) 1997-12-02
JPH08504763A (ja) 1996-05-21
AU669256B2 (en) 1996-05-30

Similar Documents

Publication Publication Date Title
CA2146973C (fr) Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques
AU696764B2 (en) Vascular endothelial growth factor 2
JP4044140B2 (ja) インスリン誘導体類とその使用
JP4854851B2 (ja) 改善された生物活性と生体適合性のためのタンパク質の部位特異的二重ポリエチレングリコール化
EP0559769B1 (fr) Mitogene de liaison d'heparine presentant une homologie avec le facteur de croissance epidermique (egf)
JP3854307B2 (ja) 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
WO2018032787A1 (fr) Protéine de fusion d'hormone de croissance humaine hautement glycosylée, son procédé de fabrication et son application
US6638912B2 (en) Peptide compositions mimicking TGF-β activity
KR20160003848A (ko) 치료용 펩티드
PT94754B (pt) Processo de obtencao de inibidor de factor de necrose tumoral e de isolamento de genes que codificam o referido inibidor
JP2003525864A (ja) 共有結合で架橋されたインスリンダイマー
JPH07500315A (ja) 骨成長因子の標的送達
KR20010006534A (ko) Ⅱ형 ｔｇｆ-베타 수용체／면역글로불린 불변 영역 융합 단백질
EP3431507B1 (fr) Protéine de fusion comprenant un facteur de croissance nerveuse et procédé de préparation et utilisation correspondants
JP2001526239A (ja) 角質細胞増殖因子−２製剤
JP2002512612A (ja) 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法
JP2002526073A (ja) 新規のヒト生長分化因子のコード配列、そのｄｎａ配列によりコードされるポリペプチド、およびこれらの製造方法。
EP1320541A2 (fr) Inhibiteurs de tgf-beta et methodes associees
CN111454371B (zh) PDL1-pHLIP、制备方法及其在治疗自身免疫病中的应用
US7282351B2 (en) Prostatic growth factor
JP2019513724A (ja) コンジュゲートされたｃ１エステラーゼインヒビター及びその使用
CZ389397A3 (cs) Stimulační faktor kostí
JP2013253079A (ja) 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
JP2000505643A (ja) レクチン様性質を有する化合物およびその生物学的応用
US6235884B1 (en) Heparin binding mitogen with homology to epidermal growth factor (EGF)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed